Company Overview

As of December 3, 2004, Cytovax Biotechnologies Inc. was acquired by Millenium Biologix Corp. in a reverse merger transaction. Cytovax Biotechnologies, Inc. engages in the research, development, and commercialization of peptide vaccines and monoclonal antibody (MAb) therapeutics for the prevention and treatment of infectious diseases, including those caused by antibiotic resistant bacteria. The company has developed Anti-Adhesin Technology and Coiled-Coil Technology that can be used to develop vaccines and therapeutic Mabs. The company’s lead product, Cytovaxine, a peptide conjugate vaccine for the prevention of infections caused by Pseudomonas aeruginosa, completed a Phase I clinical trial....

As of December 3, 2004, Cytovax Biotechnologies Inc. was acquired by Millenium Biologix Corp. in a reverse merger transaction. Cytovax Biotechnologies, Inc. engages in the research, development, and commercialization of peptide vaccines and monoclonal antibody (MAb) therapeutics for the prevention and treatment of infectious diseases, including those caused by antibiotic resistant bacteria. The company has developed Anti-Adhesin Technology and Coiled-Coil Technology that can be used to develop vaccines and therapeutic Mabs. The company’s lead product, Cytovaxine, a peptide conjugate vaccine for the prevention of infections caused by Pseudomonas aeruginosa, completed a Phase I clinical trial. The company was also developing other product candidates, including a monoclonal antibody for the treatment of Pseudomonas aeruginosa infections; and a vaccine for the prevention of infections caused by Streptococcus pneumoniae, as of March 8, 2004. The company operates in Canada. The company was formed on April 1, 1998.

Key Executives for Cytovax Biotechnologies Inc.

Similar Private Companies By Industry

Recent Private Companies Transactions